Botulinum Toxin

Part of our complete guide to Periocular Rejuvenation — this page covers botulinum (Botox®) treatment in depth.

Botulinum Toxin — Neuromodulators

Botulinum toxin type A reversibly blocks acetylcholine release at the neuromuscular junction, producing temporary, controlled weakening of injected muscles. In cosmetic practice, this smooths dynamic wrinkles — lines created by repetitive facial muscle contraction. In therapeutic use, it provides lasting relief from involuntary muscle spasms. Oculoplastic surgeons are uniquely qualified to administer periorbital injections given their deep anatomical expertise in the eyelid, orbit, and surrounding facial musculature.

How Botulinum Toxin Works

Botulinum toxin blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins inside the nerve terminal — proteins essential for vesicle fusion. Without fusion, acetylcholine cannot be released and the muscle cannot contract. Effects are temporary because nerve terminals eventually sprout new axon branches that bypass the blocked junction, which is why results last 3–6 months rather than permanently.

Mechanism of Action — Illustrated

Muscle Anatomy & Product Differences

Product Comparison — All FDA-Approved Botulinum Toxins

Six botulinum toxin type A products are currently FDA-approved in the United States. While all share the same mechanism, they differ in formulation, unit potency, onset, duration, and specific indications. These products are not interchangeable on a unit-for-unit basis — dosing must account for the conversion factor for each product.

Cosmetic Treatment Areas

Glabellar Complex (“11 Lines”)

The corrugator supercilii and procerus muscles between the brows create vertical glabellar furrows — the “11 lines” — that impart an appearance of anger or worry. This is the most common treatment area and was the first FDA-approved cosmetic indication for all products. Typical dose: 20–25 units Botox-equivalent. Reduces frowning lines and softens the glabellar area. All six FDA-approved products have at least a glabellar line indication.

Forehead Lines

The frontalis muscle creates horizontal forehead creases. Treatment requires careful dose titration — weakening the frontalis too aggressively causes brow ptosis (lowered brows), particularly in patients who habitually elevate their brows to compensate for heavy upper lids or brow ptosis. Typical dose: 10–20 units Botox-equivalent across 4–6 injection points. Brow position must be assessed before treating the forehead. Dysport may spread more than desired in this area; precise injectors may prefer Botox or Xeomin.

Crow’s Feet (Lateral Canthal Lines)

The lateral orbicularis oculi creates fan-shaped creases at the outer corners of the eyes with smiling. Small doses (6–12 units Botox-equivalent per side) injected 1 cm lateral to the orbital rim reduce these lines while preserving natural animation. Over-treatment produces a flattened, unnatural appearance. Botox Cosmetic has explicit FDA approval for lateral canthal lines.

Brow Lifting

A non-surgical brow lift is achieved by injecting small doses into the lateral orbicularis oculi just below the lateral brow tail. This relaxes the brow depressor effect of the orbicularis, allowing the frontalis to elevate the lateral brow by 1–3 mm — a subtle but effective improvement in brow arch. Best combined with conservative forehead treatment.

Bunny Lines

Diagonal creases across the nasal bridge from the nasalis muscle. Treated with 4–6 units at the nasal bridge. Commonly appear as a compensatory contraction after glabellar treatment and can be addressed at the same visit.

Lower Face & Neck

Small doses to the lip lines (orbicularis oris), chin (mentalis dimpling), and neck (platysmal bands) extend perioral and lower face rejuvenation. These areas require precise technique — functional compromise of lip movement or chewing is possible with incorrect placement. The lower face is not an area for beginners.

Choosing a Product — Clinical Guidance

Treatment Details

• In-clinic procedure — no anesthesia required; topical ice or numbing cream optional
• Fine needle (30–32G); multiple small injections at anatomically precise points
• Onset: 2–5 days depending on product; peak effect: 7–14 days
• Duration: 3–4 months for most products; up to 6 months with Daxxify
• Maintenance: Retreatment every 3–6 months to sustain results
• Touch-up: A 2-week follow-up allows refinement of asymmetry or undertreated areas
• Reconstitution: Toxin is lyophilized (freeze-dried) and reconstituted with sterile saline before use; concentration varies by practice. Xeomin is room-temperature stable before reconstitution.

Side Effects & Risks

• Bruising — common; resolves in 5–10 days. Avoiding non-essential blood thinners (e.g., aspirin, NSAIDs, fish oil) about 1 week prior may reduce risk — but never stop a prescribed anticoagulant or antiplatelet medication without first consulting the prescribing physician.
• Eyelid ptosis — the most clinically significant complication; from toxin diffusion into the levator palpebrae superioris. Most common with glabellar injections placed too close to or below the orbital rim. Produces a drooped upper eyelid. Treated with apraclonidine 0.5% drops (alpha-adrenergic agonist stimulating Müller’s muscle), which provides 1–2 mm elevation. Typically resolves as the toxin effect wears off (usually within 6–12 weeks). Risk is lowest with products with limited diffusion (Botox, Xeomin).
• Brow ptosis — from excess frontalis weakening; heavy brows drop further. Prevented by conservative dosing and sparing the inferior-central frontalis.
• Asymmetry — muscle strength varies between sides; may require touch-up injection at the 2-week visit.
• Headache — transient; occasionally reported following first treatments, resolves within 24–48 hours.
• Secondary non-response — reduced efficacy with long-term use due to neutralizing antibody formation. More common with frequent high-dose injections. Mitigated by maximizing injection intervals and minimizing dose. Switching products or using Xeomin (no complexing proteins) may help.
• Dysphagia (neck/cervical injections) — relevant for blepharospasm patients receiving high-dose injections; transient swallowing difficulty is the most common serious adverse effect at high therapeutic doses.

Therapeutic Uses

Beyond cosmetic applications, oculoplastic surgeons use botulinum toxin therapeutically for:

• Essential blepharospasm — injections into the orbicularis oculi provide 10–16 weeks of relief from involuntary eyelid closure. Botox and Xeomin have FDA approval for blepharospasm. See the Blepharospasm page for full details.
• Hemifacial spasm — unilateral facial muscle spasms most often from vascular compression of the facial nerve; treated with injections targeting the affected orbicularis, zygomaticus, and frontalis on the involved side
• Hyperhidrosis — excessive sweating of the palms, axillae, forehead, or scalp; injections reduce sweating by blocking sudomotor nerve terminals
• Migraine prevention — fixed-site PREEMPT protocol (31 injection sites, 155 units) for chronic migraine (typically administered by neurology); Botox is the only FDA-approved toxin for this indication
• Cervical dystonia — abnormal neck posturing from involuntary sternocleidomastoid and trapezius contraction; Botox, Dysport, Xeomin, and Daxxify are FDA approved